To view the latest corporate presentation please click here.
To view the presentation of the preliminary results for the year ended 31 March 2020 please click here.
A recording of the webcast can be accessed via the following link:
11 June 2020: ReNeuron Group’s (LON:RENE) Michael Hunt pitches the company to investors at the Proactive One2One Virtual Event. The company’s a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
To view the link please CLICK HERE.
CLICK HERE to view a copy of the presentation made by Pravin Dugel MD on 12 October 2019 at the American Academy of Ophthalmology Annual Meeting (AAO) in San Francisco relating to the Company’s Phase 1/2a clinical trial of its hRPC stem cell therapy in retinitis pigmentosa (RP).